Publications To Date


    Filter Publications


    Yeku O.O. et al., Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment, doi:10.1038/s41598-017-10940-8, Sci. Reports, Sep 05, 2017

    Poon E. et al., The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment, 10.1186/s40425-017-0268-8, J. Immunother. Can., Aug 15, 2017

    Yuan Y. et al., Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab, 10.1080/2162402X.2017.1363138, OncoImmunology, Aug 11, 2017

    Xu C. et al., Combination therapy with NHS-muIL12 and avelumab (anti-PD-L1) enhances antitumor efficacy in preclinical cancer models., 2017 Jul 5. pii: clincanres.0483.2017. doi: 10.1158/1078-0432.CCR-17-0483. [Epub ahead of print], Clin. Can. Res., Aug 04, 2017

    Kallert S.M. et al., Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy, 2017 May 26. doi: 10.1038/ncomms15327, Nature Commun., Aug 04, 2017

    Liu J.C. et al., Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERα- breast cancer, 2017 Jun 20. doi: 10.1371/journal.pone.0179223, PLoS ONE, Aug 04, 2017

    Chew V. et al., Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses, 2017 Jul 3. doi: 10.1073/pnas.1706559114, PNAS, Aug 04, 2017

    Chen M. et al., Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification, July 28 2017 | doi:10.1038/modpathol.2017.86, Modern Pathology, Aug 04, 2017

    Ayers, et al. Gene expression profile predicts response to pembrolizumab - VIDEO, Video, Journal of Clinical Investigation, Jun 26, 2017

    Ayers, et al. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade , Epub, Journal of Clinical Investigation (JCI), Jun 26, 2017

    Gómez-Miragaya J, et al. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population, Volumes 1 - 8 (2013 - 2017), Stem Cell Reports, May 09, 2017

    Jochems C, et al. ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody, DOI: 10.1002/ijc.30767, IJC, May 06, 2017

    Pollack S.M. et al., T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas, 10.1002/cncr.30726, Cancer, May 02, 2017

    Thieblemont C, et al. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone., 2017726984. , J. Clin. Oncol., Apr 20, 2017

    Daley D. et al., Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance, [Epub ahead of print]., Nat. Med., Apr 10, 2017